非小細胞肺癌表皮生長因子受體突變的治療：目前作用和未來觀點

作者：Sofina

原文出處

Ahmed Y, Yousif H. Treatment of epidermal growth factor receptor mutations in non-small cell lung cancer: current role and the future perspective. J Unexplored Med Data 2017;2:39-47.

DOI:10.20517/2572-8180.2017.03

摘要

管理晚期非小細胞肺癌已經變得比以往複雜得多。這部分是由於分子腫瘤學的進步使許多肺癌患者能夠進行更精確和有效的治療選擇。第一個進展是鑒定各種正在被越來越多地測試的生物標誌物，即使是一個廣泛的小組，包括我們幾年來一直聽到的一些目標物，還有其他目前仍在出現的目標物。一些最常見的生物標誌物包括表皮生長因子受體以及間變性淋巴瘤激酶。此外，儘管事實上，我們已經知道了克爾斯坦大鼠肉瘤數十年，但針對這種分子的療法更加難以捉摸。此外，其他潛在有用的治療靶點不斷湧現，並納入國家綜合癌症網路指南。其中幾個具有足夠強大的第二階段（或更多）數據，引導他們認為這已超過表皮生長因子受體，間變性淋巴瘤激酶和c-ros癌基因1. 表皮生長因子受體敏感突變和間變性淋巴瘤激酶重排患者的臨床臨床試驗數據顯示，酪氨酸激酶抑制劑與標準化療相比，具有優越的無進展生存期和反應率。

關鍵詞：表皮生長因子受體，肺癌，酪氨酸激酶抑制劑。

Managing advanced non-small cell lung cancer has become far more complex than in the past. This in part is due to the fact that advances in molecular oncology allow for far more refined and effective treatment options for many lung cancer patients. One of the first advances was the identification of various biomarkers that are increasingly being tested for, even as a broad panel, that include some targets that we have been hearing about for a few years and others that are still emerging. Some of the most common biomarkers include epidermal growth factor receptor (EGFR) as well as anaplastic lymphoma kinase (ALK). Also, despite the fact that we have known about Kirsten rat sarcoma for decades, therapies targeting this molecule has been more elusive. In addition, other potentially useful therapeutic targets are constantly emerging and incorporated in the National Comprehensive Cancer Network guidelines. Several of these have phase 2 (or beyond) data that have been compelling enough to lead to them being considered beyond EGFR, ALK, and c-ros oncogene 1. Emerging clinical trial data for patients with EGFR-sensitizing mutations and ALK rearrangements, showed that tyrosine kinase inhibitors offer superior progression free survival and response rates over standard chemotherapy.

Keywords:Epidermal growth factor receptor, lung cancer, tyrosine kinases inhibito.

各位讀者可複製此鏈接到瀏覽器中打開。

http://jumdjournal.net/article/view/1940

喜歡這篇文章嗎？立刻分享出去讓更多人知道吧！